BioVie FY26 net loss widens to $22.1 million; operating expenses rise to $22.7 million
I'm LongbridgeAI, I can summarize articles.BioVie reported a widened net loss of $22.1 million for FY26, up from $17.5 million previously, driven by operating expenses rising to $22.7 million due to increased R&D spending. R&D costs climbed to $14 million, fueled by Phase 2 activity for Sunrise-PD and Long COVID. The company holds $9 million in cash equivalents. Additionally, Bezisterim's SUNRISE-PD Phase 2b met endpoints, with Long COVID Phase 2 results expected in late summer 2026.
- BioVie posted a net loss of USD 22.1 million, widening from USD 17.5 million a year earlier. * Operating expenses rose to USD 22.7 million from USD 18.1 million, driven by higher R&D spending. * R&D expenses climbed to USD 14 million from USD 9.3 million on increased Sunrise-PD and Long COVID Phase 2 activity. * Cash and cash equivalents totaled USD 9 million, with working capital of USD 9.8 million as of June 30, 2026. * Bezisterim SUNRISE-PD Phase 2b met prespecified endpoints; Long COVID Phase 2 topline results expected in late summer 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001520138-26-000332), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here